Skip to main content

Qiagen Licenses RT-PCR IP From Roche, Ortho Clinical Diagnostics

NEW YORK (GenomeWeb News) — Qiagen on Monday said it has licensed real-time PCR technology from Roche and from Ortho Clinical Diagnostics.
Under the agreement with Roche, Qiagen said it expands an existing arrangement to include all of Roche’s RT-PCR patents and pending patents. Qiagen said the agreement includes rights to patents for enzymes, improved PCR, and pathogen-specific patents.
Through the Ortho agreement, Qiagen has licensed rights to patents for a taq-polymerase antibody method that speeds up the activation of PCR enzymes in the early phases of the process.
Qiagen said that these licenses expand its portfolio of assays and diagnostics using “almost any” basic IVD-related PCR and real-time PCR.
Financial terms of the agreements were not released.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.